Abstract
Objectives:
To find a biomarker to predict the prognosis of acute on chronic hepatitis B liver failure (ACHBLF).
Methods:
Expression gene profiles in wnt pathway were determined in serum from 63 patients with ACHBLF, 60 patients with chronic hepatitis B (CHB) and 30 healthy controls (HCs).
Results:
Serum wnt5a concentration of 1.553 ng/ml showed a poor prognosis with a sensitivity of 69.23% and a specificity of 83.33% in ACHBLF patients.
Conclusions:
Serum wnt5a gene expression might be a potential biomarker for predicting the prognosis of ACHBLF.
Keywords:
acute on chronic hepatitis B liver failure; prognosis; sfrp1; wnt5a.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute-On-Chronic Liver Failure / blood*
-
Acute-On-Chronic Liver Failure / mortality
-
Acute-On-Chronic Liver Failure / virology
-
Adult
-
Case-Control Studies
-
DNA Methylation
-
Female
-
Gene Expression
-
Hepatitis B, Chronic / blood*
-
Hepatitis B, Chronic / mortality
-
Humans
-
Intercellular Signaling Peptides and Proteins / blood
-
Intercellular Signaling Peptides and Proteins / genetics
-
Kaplan-Meier Estimate
-
Male
-
Membrane Proteins / blood
-
Membrane Proteins / genetics
-
Middle Aged
-
Prognosis
-
Promoter Regions, Genetic
-
Proto-Oncogene Proteins / blood*
-
Proto-Oncogene Proteins / genetics
-
ROC Curve
-
Wnt Proteins / blood*
-
Wnt Proteins / genetics
-
Wnt-5a Protein
Substances
-
Intercellular Signaling Peptides and Proteins
-
Membrane Proteins
-
Proto-Oncogene Proteins
-
SFRP1 protein, human
-
WNT5A protein, human
-
Wnt Proteins
-
Wnt-5a Protein